{"name":"Fovea Pharmaceuticals SA","slug":"fovea-pharmaceuticals-sa","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CsA high dose","genericName":"CsA high dose","slug":"csa-high-dose","indication":"Organ transplantation","status":"phase_2"},{"name":"CsA low dose","genericName":"CsA low dose","slug":"csa-low-dose","indication":"Prevention of organ rejection in kidney transplant patients","status":"phase_2"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"FOV1101-00","genericName":"FOV1101-00","slug":"fov1101-00","indication":"Inherited retinal dystrophies","status":"phase_2"},{"name":"PA","genericName":"PA","slug":"pa","indication":"Inherited retinal diseases (e.g., Retinitis Pigmentosa, Leber Congenital Amaurosis)","status":"marketed"}]}],"pipeline":[{"name":"CsA high dose","genericName":"CsA high dose","slug":"csa-high-dose","phase":"phase_2","mechanism":"Calcineurin inhibitor","indications":["Organ transplantation"],"catalyst":""},{"name":"CsA low dose","genericName":"CsA low dose","slug":"csa-low-dose","phase":"phase_2","mechanism":"CsA works by inhibiting calcineurin, a protein phosphatase involved in the activation of T-lymphocytes.","indications":["Prevention of organ rejection in kidney transplant patients"],"catalyst":""},{"name":"FOV1101-00","genericName":"FOV1101-00","slug":"fov1101-00","phase":"phase_2","mechanism":"FOV1101-00 is a small molecule that targets retinal degeneration through modulation of cellular survival pathways in the eye.","indications":["Inherited retinal dystrophies","Age-related macular degeneration"],"catalyst":""},{"name":"PA","genericName":"PA","slug":"pa","phase":"marketed","mechanism":"PA is a prodrug that is converted to its active form to modulate retinal function and treat vision disorders.","indications":["Inherited retinal diseases (e.g., Retinitis Pigmentosa, Leber Congenital Amaurosis)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2009-10-01","type":"deal","source":"RTTNews","summary":"Sanofi-aventis To Buy Privately-held Fovea For EUR 370 Mln; Signs Collaboration, Licensing Deal With Merrimack - Update - RTTNews","headline":"Sanofi-aventis To Buy Privately-held Fovea For EUR 370 Mln; Signs Collaboration, Licensing Deal With Merrimack - Update","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_2":3,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}